This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Sanofi to Buy Vaccine Biotech Protein Sciences for $650M
by Zacks Equity Research
Sanofi (SNY), on Monday, announced plans to buy a Meriden, CT-based private vaccine biotech, Protein Sciences for an upfront payment of $650 million.
Sanofi Versus AstraZeneca: Large Cap Pharma Stock Faceoff
by Zacks Equity Research
Both stocks carry a Zacks Rank #2 (Buy).
Pharma Stock Roundup: Sanofi RA Drug Gets EU Nod, Merck CETP Inhibitor Surprises
by Arpita Dutt
Merck's (MRK) results on its CETP inhibitor took the investment community by surprise while Sanofi gained EU approval for its rheumatoid arthritis (RA) drug.
Robust 1H for Pharma/Biotech Sector, 3 Big Stocks to Buy
by Zacks Equity Research
The pharma and biotech industry has been blessed with good health in the first half of the year.
AstraZeneca's Faslodex Recommended by CHMP for 1st Line Use
by Zacks Equity Research
AstraZeneca PLC (AZN) announced that the CHMP of the European Medicines Agency has adopted a positive opinion recommending the marketing authorisation of Faslodex for 1st-line treatment for postmenopausal women with HR+ advanced breast cancer.
Minerva On Track to Initiate Phase III Schizophrenia Study
by Zacks Equity Research
Minerva Neurosciences, Inc. (NERV) announced that it is on track to begin phase III studies on its key schizophrenia pipeline candidate MIN-101 in the second half of this year, as planned.
Novo Nordisk's Victoza Gets FDA Panel Nod for Label Expansion
by Zacks Equity Research
Novo Nordisk A/S (NVO) announced that the Endocrinologic and Metabolic Drugs Advisory Committee of the FDA voted 17-2 in favor of Victoza that the drug provides substantial evidence of cardiovascular risk reduction in patients with type II diabetes.
5 Reasons Why You Should Invest in AstraZeneca (AZN) in 2017
by Zacks Equity Research
London-based pharma giant, AstraZeneca plc (AZN) has a strong product portfolio and is one of the key players in the global cardiovascular market.
Clovis Up Nearly 50% on Solid Data from Ovarian Cancer Study
by Zacks Equity Research
Clovis Oncology, Inc. (CLVS) shares soared nearly 50% on Monday after it announced positive top-line results from a pivotal late-stage maintenance study on its newly launched ovarian cancer drug, Rubraca.
4 Buy-Ranked Large Cap Pharma Stocks to Add to Your Portfolio
by Arpita Dutt
The Zacks-categorized Large Cap Pharmaceuticals industry is among the top 21% of the 256 Zacks-ranked industries -- here is a look at 4 top-ranked stocks from this sector.
Nektar (NKTR) Stock Rallied Almost 50% This Year: Here's Why
by Zacks Equity Research
Shares of Nektar Therapeutics (NKTR) are up almost 48% this year so far, outperforming the Zacks classified Medical-Drugs industry's registered increase of 3.6% during this period.
Here's Why Clovis (CLVS) Stock is Up Almost 350% in One Year
by Zacks Equity Research
Shares of Clovis Oncology, Inc. (CLVS) continue to witness an upside. The uptrend started in the third quarter of 2016.
Pharma Stock Roundup: J&J, Lilly Present Data, Merck Keytruda Study Enrolment Paused
by Arpita Dutt
Merck (MRK) paused patient enrolment in a couple of studies being conducted with its anti-PD-1 therapy, Keytruda.
Pfizer (PFE) Buys Exclusive EU Rights to Anti-Fungal Drug
by Zacks Equity Research
Pfizer, Inc. (PFE) announced a deal to buy exclusive EU commercialization rights to an anti-fungal treatment, Cresemba from Swiss pharma company, Basilea Pharmaceutica Ltd.
J&J's Invokana Lowers Heart Issues, Raises Amputation Risk
by Zacks Equity Research
Johnson & Johnson (JNJ) announced data from a large CANVAS outcomes program, which demonstrated that its type II diabetes drug Invokana (canagliflozin) was successful in reducing the risks of heart attacks and strokes.
AstraZeneca (AZN) Divests Migraine Drug Rights Beyond Japan
by Zacks Equity Research
AstraZeneca PLC (AZN) has inked a deal to sell the global rights of migraine treatment drug Zomig (zolmitriptan) outside Japan to Grunenthal, a German pharmaceutical company.
Intellipharmaceutics Announces Launch of Generic Seroquel XR
by Zacks Equity Research
Intellipharmaceutics International Inc. (IPCI) announced the launch of a generic version of schizophrenia drug Seroquel XR by its marketing and distribution partner in the U.S, Mallinckrodt Public Limited Company
Incyte Provides Updated Data on Cancer Combination Therapies
by Zacks Equity Research
Incyte along with partner Bristol-Myers Squibb announced updated data from phase I/II study, ECHO-204, evaluating epacadostat in combination with Opdivo for the treatment of squamous cell carcinoma of the head and neck and melanoma.
Incyte Announces Data on Enzyme Inhibitor with Keytruda
by Zacks Equity Research
Incyte Corporation (INCY) and Merck & Co. (MRK) announced an updated data from the advanced non-small cell lung cancer patient cohort of the ongoing phase I/II ECHO-202 study.
Big Pharma Diabetes Drugs Not So Sweet. What's in Store?
by Zacks Equity Research
Aales of diabetes drugs from most large pharma companies slipped in the first quarter.
Are Nektar's (NKTR) Key Drugs Set to Drive Growth in 2017?
by Zacks Equity Research
On May 29, 2017, we issued an updated report on Nektar Therapeutics (NKTR).
Sanofi (SNY) Stock Continues to Gain on Key Drug Approvals
by Zacks Equity Research
After declining in 2016, share price of French pharma giant Sanofi (SNY) has picked up in 2017.
AstraZeneca's Bydureon Fails to Reduce Cardiovascular Risk
by Zacks Equity Research
AstraZeneca plc (AZN) announced top-line results from the EXSCEL study evaluating the cardiovascular (CV) safety profile of its type II diabetes drug Bydureon.
The Zacks Analyst Blog Highlights: Oracle, Chubb, AstraZeneca, Estee Lauder and Aflac
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Oracle, Chubb, AstraZeneca, Estee Lauder and Aflac
AstraZeneca Sells Marketing Rights to Seloken in Europe
by Zacks Equity Research
AstraZeneca plc (AZN) announced that it has signed an agreement with Recordati S.p.A, granting commercial rights to Seloken/Seloken ZOK and associated Logimax fixed-dose combination to the latter in European markets.